A retrospective review of the persistence of bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population.

Aim: To describe the persistence of biologic disease modifying anti-rheumatic drugs (bDMARDs) in Australian rheumatoid arthritis (RA) patients, and assess the influence of methotrexate and other conventional DMARD (cDMARD) concomitant medications, and treatment line on bDMARD persistence and glucocorticoids usage.

Authors: Graeme Jones, Stephen Hall, Paul Bird, Geoff Littlejohn, Kathleen Tymms, Peter Youssef, Eric Chung, Rina Barrett, Peter Button
International Journal of Rheumatic Diseases 2018; 21: 1581–1590

Download document